Mitoxantrone in the treatment of severe multiple sclerosis;Mitoxantron (Novantron®) zur therapie der schwer verlaufenden multiplen sklerose

Nervenarzt

Volumn 70, Issue 8, 1999, Pages 723-731

  Cursiefen, S ^a,b   Flachenecker, P ^a   Rieckmann, P ^a   Toyka, K V ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Immunosuppression; Mitoxantrone; Multiple sclerosis; Rescue therapy; Treatment

Indexed keywords

ANTHRAQUINONE DERIVATIVE; AZATHIOPRINE; CYCLOPHOSPHAMIDE; INTERFERON BETA SERINE; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ARTICLE; CLINICAL ARTICLE; DISABILITY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; ADULT; BRAIN; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; MIDDLE AGED; REVIEW; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BRAIN; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033174820     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001150050501     Document Type: Article

References (25)

1. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, Elizur A, Goldhammer Y, Sarova-Pinhas I (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Neurology 50:398-402
2. Bastaniello S, Pozzilli C, D'Andrea F, Millefiorini E, Trojano M, Morino S, Gasperini C, Bozzao A, Gallucci M, Andreula C, Bozzao L, Gambi D, Prencipe M (1994) A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 21:266-270
3. DeCastro S, Cartoni D, Millefiorini E, Funaro S, Gasperini C, Morino S, Tallarico D, Beni S (1995) Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. J Clin Pharmacol 35:627-632
4. Dollery C (1991) Mitozantrone. In: Dollery C (ed) Therapeutic drugs. Churchill Livingstone, Edinburgh, pp M218-M222
5. Edan G, Miller D, Clanet M, Confavreux C, LyonCaen O, Lubetzki C, Brochet B, Berry I, Rolland Y, Froment J-C, Dousset V, Cabanis E, Iba-Zizen M-T, Gandon J-M, Lai HM, Moseley I, Sabouraud O (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112-118
6. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 349:589-593
7. Faulds D, Balfour JA, Chrisp P, Langtry HD (1991) Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer. Drugs 41:400-449
8. Fidler JM, DeJoy SQ, Gibbons JJJr (1986) Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 137:727-732
9. Fidler JM, DeJoy SQ, Smith FR 3d, Gibbons JJ Jr (1986) Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 136:2747-2754
10. Gonsette RE, Demonty L (1990) Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 40 [Suppl 1]: 261
11. Gonsette RE (1996) Mitoxantrone immunotherapy in multiple sclerosis. Multiple Sclerosis 1:329-332
12. Hartung HP, Gonsette R and the MIMS-Study Group (1998) Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind european phase III multicenter study - clinical results. Multiple Sclerosis 4:325
13. Kappos L, Gold R, Künstler E, Rohrbach E, Heun R, Städt D, Hofmann E (1990) Mitoxantrone (Mx) in the treatment of rapidly progressive MS: a pilot study with serial gadolinium (Gd)-enhanced MRI. Neurology 40 [Suppl I]:261
14. Krapf H, Mauch E, Fetzer U, Laufen H, Kornhuber HH (1995) Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology 37:113-119
15. Krapf H, Morrissey SP, Zenker O, Gonsette R, Hartung HP and the MIMS-Study Group (1998) Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind european phase III multicenter study - MRI results. Multiple Sclerosis 4:380
16. Levine S, Saltzman A (1986) Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J Neuroimmunol 13:175-181
17. Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H (1992) Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 242:96-102
18. Millefiorini E, Gasperini C, Pozzilli C, D' Andrea F, Bastianello S, Trojano M, Morino S, Brescia Morra V, Bozzao A, Calo A, Bernini ML, Gambi D, Prencipe M (1997) Randomized placebocontrolled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244:153-159
19. Noseworthy JH, Hopkins MB, Vandervoort MK, Karlik SJ, Lee DH, Penman M, Rice GPA, Grinwich KD, Cauvier H, Harris BJ, Ebers GC (1993) An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 43:1401-1406
20. Noseworthy JH, Lee D, Penman M, Hopkins M, Vandervoort MK, Karlik SJ, Rice GPA, Grinwich KD, Ebers GC (1991) A phase II evaluation of mitoxantrone HCI in the treatment of progressive multiple sclerosis. Neurology 41 [Supp 1]:146
21. Report of the Quality Standards Subcommittee of the American Academy of Neurology (1994) Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 44:1537-1540
22. Ridge SC, Sloboda AE, McReynols RA, Levine S, Oronsky AL, Kerwar SS (1985) Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 35:35-42
23. Watson CM, Davison AN, Baker D, O'Neill JK, Turk JL(1991) Suppression of demyelination by mitoxantrone. Int J Immunopharmacol 13:923-930
24. Weber F, Rieckmann P (1995) Pathogenese und Therapie der multiplen Sklerose. Nervenarzt 66:150-155
25. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, Herndon R, Lehrich JR, Hauser SL, Turel A, Fisher M, Birnbaum G, McArthur J, Butler R, Moore M, Sigsbee M, Safran A (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43:910-918